Journal of Hematology & Oncology

Article	Citations
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	722
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	688
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	686
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	661
Recent advances in targeting protein degradation for tumor immunotherapy	651
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	577
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	443
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	421
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	410
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	380
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	366
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	354
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	343
Cancer vaccines: current status and future directions	330
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	300
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	297
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	293
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	266
Landscape of biallelic DNMT3A mutant myeloid neoplasms	263
Personalized nanovaccines for treating solid cancer metastases	241
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	226
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	221
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	218
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	218
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	213

Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	208
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	206
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	201
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	198
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	189
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	189
Ferroptosis: principles and significance in health and disease	189
Recent advances in therapeutic strategies for non-small cell lung cancer	184
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	182
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	179
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	177
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	172
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	168
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	165
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	163
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	160
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	152
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	149
Small RNA modifications: regulatory molecules and potential applications	149
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	146
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	146
3D chromatin architecture and transcription regulation in cancer	141
Recent advances in targeted strategies for triple-negative breast cancer	141
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	138
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	138
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	138
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	137
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	137
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	136
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	135
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	131
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	130
A single-cell and spatially resolved atlas of human osteosarcomas	129
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	129
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	129
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	128
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	128
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	122
Target neutrophil heterogeneity and plasticity in cancer	121
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	120
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	119
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	116
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	115
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	115
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	115
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	114
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	114
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	112
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	112
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	112

Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	111
The functional and clinical roles of liquid biopsy in patient-derived models	106
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	105
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	104
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	104
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	103
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	97
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	96
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	94
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	94
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	93
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	93
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	91
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	91
Worked to the bone: antibody-based conditioning as the future of transplant biology	91
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	91
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	90
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	90
Challenges and new technologies in adoptive cell therapy	88
Gastric cancer treatment: recent progress and future perspectives	85
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	84
The long and short non-coding RNAs modulating EZH2 signaling in cancer	83
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	83
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	82
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	82
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	82
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	82
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	80
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	80
Targeting GPRC5D for multiple myeloma therapy	79
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	79
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	78
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	75
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	74
Metabolic reprogramming in the tumor microenvironment of liver cancer	74
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	74
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	73
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	73
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	72
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	72
Correction: Immunosenescence: a key player in cancer development	71
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	70
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	69
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	68
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	68
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	68
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	67
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	66
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	66
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	65
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	65
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	63
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	63
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	62
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	61
Advances in targeting histone deacetylase for treatment of solid tumors	61
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	60
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	60
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	59
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	59
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	59
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	58
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	57
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	57
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	57
C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction	56
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	56
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	56
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	55
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	55
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	55
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study	54
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	54
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	54
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors	54
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	53
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study	53
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC	52
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant	50
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer	49

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades	49
Targeting inflammation as cancer therapy	48
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies	47
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy	47
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics	47
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma	46
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease	45
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting	44
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting	44
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolyt	44
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead	43
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting	43
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease	43
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy	43
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types	43
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential	42
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies	42
Genitourinary cancers updates: highlights from ASCO 2023	41
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed pri	41
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting	40
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia	40
Novel strategies for cancer immunotherapy: counter-immunoediting therapy	40
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies	40
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy	40
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial	39
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma	39
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis	39
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer	39
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients	38
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer	38
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	38
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	37
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena	37
Involvement of inflammasomes in tumor microenvironment and tumor therapies	37
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	37
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	37
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	36
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior	36
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	36
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated resu	35
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes	34
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	34
Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer	34
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance	34
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis	33
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	33
Liquid biopsy: current technology and clinical applications	33
Recent advances in therapeutic strategies for triple-negative breast cancer	33
Consensus, debate, and prospective on pancreatic cancer treatments	33
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	33
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	32
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation	31
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting	31
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers	30
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality	30
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation	30
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022	30
Correction: The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	30
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment	30
Lipid-based nanosystems: the next generation of cancer immune therapy	29
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities	29
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial	29
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	29
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer	27
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting	27
Targeting FGFR for cancer therapy	27
Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor	27
LncRNA-encoded peptides in cancer	27
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA	26
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies	26
Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients	26
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia	25
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial	24
Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients	24
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	24
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	23
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study	23
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment	23
Altered pathways and targeted therapy in double hit lymphoma	23
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives	23
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors	23
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide	22
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia	22
Recent advances in S-palmitoylation and its emerging roles in human diseases	22
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	22
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Conso	22
Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia	21
Emerging evidence and treatment paradigm of non-small cell lung cancer	21
Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells	21
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia	20
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells	20
Protein degradation: expanding the toolbox to restrain cancer drug resistance	20
Correction: CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells	19
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	19
Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications	19